Similar companies
Income Statement (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Revenue | 11M | 73.8% |
| Gross Profit | 11M | 73.8% |
| Operating expense | 46M | 30.5% |
| Net Income | -32M | 23.6% |
| EBITDA | -32M | 13.7% |
Balance Sheet (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Total Assets | 265M | 10.5% |
| Total Liabilities | 111M | 9.3% |
| Total Equity | 154M | 11.3% |
| Shares Outstanding | 73M | 2.2% |
Cash Flow (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Cash from operations | -31M | 158.8% |
| Cash from investing | 4.1M | 89.5% |
| Cash from financing | 7.8M | 0% |
EPS
Financial Highlights for C4 Therapeutics in Q3 '25
C4 Therapeutics reported a revenue of 11M, which is a 73.8% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 11M, marking a 73.8% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Operating Expenses for this period were 46M, showing a 30.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -32M, showing a -23.6% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -32M, showing a -13.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
C4 Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
